Not available
Quote | Sangamo Therapeutics Inc. (NASDAQ:SGMO)
Last: | $0.4596 |
---|---|
Change Percent: | -3.72% |
Open: | $0.446 |
Close: | $0.4596 |
High: | $0.4794 |
Low: | $0.42 |
Volume: | 1,989,152 |
Last Trade Date Time: | 07/16/2024 03:00:00 am |
News | Sangamo Therapeutics Inc. (NASDAQ:SGMO)
2024-05-30 16:55:01 ET In its annual 2024 Russell index reconstitution, about 213 companies will be added and 198 deleted from the Russell Microcap Index. Read the full article on Seeking Alpha For further details see: Nektar, Verastem among healthcare additions in Russe...
2024-05-30 15:54:21 ET The Russell 3000 index will have a new look on June 28, after the market closes, when 225 securities will be added and 144 securities will be deleted as part of the annual reconstitution. Following are some notable healthcare companies which will be added and ...
Message Board Posts | Sangamo Therapeutics Inc. (NASDAQ:SGMO)
Subject | By | Source | When |
---|---|---|---|
znewcar1: $SGMO 20% v5,1M c1.64 f192,9MH1.6795 ML1.35=LL | znewcar1 | investorshangout | 04/13/2023 9:33:16 PM |
I'm not ready to put a fork in | The Canes | investorshub | 03/29/2023 3:43:01 PM |
The company is essentially dead. | jondoeuk | investorshub | 03/17/2023 11:44:30 PM |
A double whammy https://www.marketscreener.com/quote/stock/SANGAMO-THERAPEUTICS- | jondoeuk | investorshub | 03/17/2023 11:43:59 PM |
Are you familiar with EDIT? How well they | jondoeuk | investorshub | 02/17/2023 1:37:43 AM |
News, Short Squeeze, Breakout and More Instantly...
Sangamo Therapeutics Inc. Company Name:
SGMO Stock Symbol:
NASDAQ Market:
Sangamo Therapeutics Inc. Website:
2024-05-15 13:30:05 ET H.C. Wainwright analyst issues UNDERPERFORM recommendation for SGMO on May 15, 2024 11:01AM ET. The previous analyst recommendation was Underperform. SGMO was trading at $0.5901 at issue of the analyst recommendation. The overall analyst consensus ...
Showcased 20 presentations at the 27 th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting demonstrating progression of neurology-focused preclinical pipeline, including additional data from novel delivery capsid, STAC-BBB, that demonstrated industry-leading blood-brain barrie...
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today presented pre-clinical data showcasing its novel next-generation integrase technology engineered to enable large-scale genome editing. Building on Sangamo’s deep expertise in protein-DNA interactions derived from...